This technology is a new tumorigenic cell line from the human prostate carcinoma cell line PC-3. These cell lines, known as PC-3/IF, when implanted in the femurs of nude mice, provide a xenograft tumor model of bone metastatic prostate carcinoma. The PC-3/IF cell lines are highly tumorigenic, with tumor cells replacing the marrow cells in the bone cavity, invading adjacent bone and muscle tissue to ultimately form a palpable tumor at the hip joint.
Background & Unmet Need:
Approximately 70% of people with advanced prostate cancer have bone metastasis; bone is commonly the first area of metastasis in many types of cancers. Usually, metastasis occurs in the bones with the greatest blood supply, including bones in the spine, pelvis, ribs, and thighs. In most cases, treatment of bone metastasis involves treatment of the primary cancer. Thus, options of treatment for bone metastasis vary depending on the type and stage of tumor progression. Treatment of disseminated disease remains palliative. This bone tumor model in mice can be used to study new drugs for the treatment of prostate carcinoma bone metastases and to study mechanisms of bone tumor growth.
Technology Description:
This is a new tumor model modified from a previous model. The procedure of intrafemoral injection was modified and improved upon. New cell lines were generated from bone tumors, which are more tumorigenic and grow with faster kinetics. This results in a faster tumor model of 40-45 days. PC-3 is a human prostatic carcinoma tumor cell line isolated from bone metastases that is androgen independent. To develop a bone tumor model for prostate carcinoma, cells were cultured in vitro, then injected into the femur cavity via the knee cap in anesthetized male Balb/c nude mice.
Commercial Applications:
This bone tumor model in mice can be used to:
- Study new drugs for the treatment of prostate carcinoma bone metastases
- Study mechanisms of bone tumor growth
Stage of Development:
Preclinical; animal studies performed
Competitive Advantages:
- Nude mouse model will not reject human transplant due to immunodeficiency status, allowing in vivo study of human tumors
Intellectual Property Status:
No patent information available
Related Publications or Citations of Work:
Triest JA, Grignon DJ, Cher ML, Kocheril SV, Montecillo EJ, Talati B, Tekyi-Mensah S, Pontes JE, Hillman GG. (1998) Systemic interleukin 2 therapy for human prostate tumors in a nude mouse model. Clin Cancer Res. 4(8):2009-14.